Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh
Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh
Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Galapagos NV:<br />
Onno van de Stolpe (CEO)<br />
GenDX:<br />
Wietse Mulder (Managing Director) and Maarten<br />
Penning (Business Development Manager)<br />
ProFibrix:<br />
Jan Öhrström (CEO) and Jaap Koopman<br />
(Chief Scientific Officer)<br />
Pwc:<br />
Arwin van der Linden (Partner)<br />
The Hubrecht Institute:<br />
Hans Clevers (Director)<br />
Thuja Capital:<br />
Harrold van Barlingen (Managing Partner)<br />
i-optics:<br />
Jeroen Cammeraat (CEO)<br />
to-BBB:<br />
Willem van Weperen (CEO)<br />
Kempen & Co:<br />
Oscar Izeboud (Managing Director Corporate<br />
Finance, Head of <strong>Life</strong> <strong>Sciences</strong>) and Ivo Piest<br />
(Executive Director Corporate Finance)<br />
Others:<br />
Ronald Brus (former CEO of Crucell and life sciences<br />
entrepreneur)<br />
<strong>Life</strong> Science Partners:<br />
René Kuijten (General Partner) and John de Koning<br />
(Partner)<br />
Merck Serono:<br />
Roel Bulthuis (Head of Merck Serono Ventures)<br />
The Ministry of Health, Welfare and Sport:<br />
Hugo Hurts (Director Pharmaceutical Affairs and<br />
Medical Technology) and Frank Flier (Senior Adviser)<br />
The Netherlands Biotech Industry Association<br />
(Niaba):<br />
Jan Wisse (Managing Director)<br />
Pharming Group NV:<br />
Sijmen de Vries (CEO)<br />
<strong>Life</strong> <strong>Sciences</strong> <strong>Outlook</strong> <strong>2012</strong> <strong>Dutch</strong> <strong>biotech</strong> <strong>companies</strong>: from start-up to exit<br />
43
Change language